Patents Assigned to TRUE HEALTH IP LLC
-
Patent number: 10475536Abstract: This invention relates to methods for predicting likelihood of a subject having abnormal glucose tolerance based on analyzing a combination of three or more biomarkers relating to specific physiological processes. This invention also relates to methods of accessing insulin sensitivity in a subject based on analyzing a combination of three or more biomarkers relating to specific physiological processes. The method has a clinical utility in correct and quick assessment of a subject's glucose tolerance and risk of developing diabetes or cardio-diabetic conditions and comorbidities.Type: GrantFiled: July 18, 2014Date of Patent: November 12, 2019Assignee: True Health IP LLCInventor: James Viktor Pottala
-
Patent number: 10401370Abstract: The application describes methods for determining the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample using enzyme linked immunosorbent assay (ELISA). The methods described herein significantly improve lipoprotein ELISA methods and devices capable of quantifying particle numbers and population mass of Lp(a) particles. This technology offers a method for the efficient and cost-effective measurement of specific Lp(a) in a rapid, low-cost format, rather than limited measurement of Lp(a) concentration in patient tissues. The ability to measure the particle number and/or molar mass of lipoprotein(a) subform(s) in a biological sample also provides a useful diagnostic tool for assessing cardiovascular risk in a subject.Type: GrantFiled: October 27, 2015Date of Patent: September 3, 2019Assignee: True Health IP LLCInventors: Philip Guadagno, Erin Grace Summers Bellin, Daniel M. Hoefner, Mohmed Ashmaig
-
Patent number: 10191032Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.Type: GrantFiled: January 13, 2014Date of Patent: January 29, 2019Assignee: True Health IP LLCInventors: Steve Varvel, Rebecca E. Caffrey, James V. Pottala
-
Patent number: 10076732Abstract: A lab rack rotator includes a motor coupled to a shaft arranged to rotate in at least one direction in response to the motor. One or more mounts are located along the surface of the shaft and are configured to receive a lab sample rack which holds a plurality of lab samples contained in lab sample containers such as test tubes. Rotation of the shaft permits inversion of the plurality of lab samples, for instance whole blood samples. The lab rack rotator increases the number of lab samples that may be agitated in an automated process while decreasing the amount of time required for necessary pre-testing agitation of samples.Type: GrantFiled: November 7, 2013Date of Patent: September 18, 2018Assignee: True Health IP LLCInventors: Greg Kontos, Jobin Abraham, Jason Branch, Will Renzulli, Ali Safavi
-
Patent number: 9915645Abstract: This invention relates to a method for detecting the presence of or likelihood of a patient of developing occult pancreatic beta cell dysfunction, and a method for detecting the presence of or likelihood of a patient of developing clinically significant post-prandial hyperglycemia. The methods involve (a) measuring a level of alpha-hydroxybutyrate (AHB) in a single fasting baseline biological sample of the patient; (b) comparing the level of AHB in the single fasting baseline biological sample to a reference AHB level; and (c) determining the presence of or likelihood of developing the disorder in the patient based on the comparison in step (b). An increased AHB level at fasting baseline indicates that a normoglycemic, normo-insulinemic and/or non-dyslipidemic patient has developed or has an increased likelihood of developing occult pancreatic beta cell dysfunction.Type: GrantFiled: January 13, 2014Date of Patent: March 13, 2018Assignee: True Health IP LLCInventors: Steve Varvel, Rebecca E. Caffrey, James V. Pottala
-
Patent number: 9810697Abstract: The invention relates to biomarkers associated with Diabetes, including protein and lipid metabolite biomarkers, methods of using the biomarkers to determine the risk that an individual will develop Diabetes, and methods of screening a population to identify persons at risk for developing Diabetes and other pre-diabetic conditions.Type: GrantFiled: November 18, 2015Date of Patent: November 7, 2017Assignee: True Health IP, LLCInventors: Michael P. McKenna, Steve M. Watkins
-
Patent number: 9759682Abstract: A fluid applicator device includes an applicator body having a surface that is generally planar. A plurality of aligned applicator teeth extend from said applicator body. Each applicator tooth extends longitudinally from said applicator body along a length from a base of the applicator tooth proximate to the applicator body to a tip of the applicator tooth distal to the applicator body. At least one applicator tooth of the plurality of aligned applicator teeth has a width that is greater at the base than at the tip. A method for depositing a liquid sample on a substrate using the fluid applicator device is also disclosed.Type: GrantFiled: August 8, 2014Date of Patent: September 12, 2017Assignee: True Health IP LLCInventor: Philip Guadagno
-
Patent number: 9740819Abstract: A method of determining risk of diabetes is provided. In one embodiment, the method comprises: a) measuring the levels of a plurality of biomarkers in a blood samples obtained from a patient, wherein the plurality of biomarkers comprises at least five of the following biomarkers: glucose, adiponectin, CRP, IL2RA, ferritin, insulin and HbAIc; b) calculating a diabetes risk score for the patients using the levels and, optionally, patient age and/or gender. Results obtained from performing the assay on a reference population are similar or identical to those obtained using Formula I.Type: GrantFiled: October 28, 2010Date of Patent: August 22, 2017Assignee: TRUE HEALTH IP LLCInventors: Michael P. McKenna, Michael Rowe, Edward J. Moler, Jr., Robert W. Gerwien
-
Patent number: 9689880Abstract: Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.Type: GrantFiled: May 5, 2015Date of Patent: June 27, 2017Assignee: TRUE HEALTH IP LLCInventors: Mickey S. Urdea, Michael P. McKenna, Patrick A. Arensdorf